Skip Navigation


NDT Advance Access originally published online on March 8, 2008
Nephrology Dialysis Transplantation 2008 23(6):1816-1818; doi:10.1093/ndt/gfn052
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/6/1816    most recent
gfn052v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chadban, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chadban, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


New-onset diabetes after transplantation—should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients

Steven Chadban

Department of Renal Medicine, Royal Prince Alfred Hospital, NSW 2050, Australia

Correspondence and offprint requests to: Steven Chadban, Department of Renal Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. E-mail: steve.chadban@sswahs.nsw.gov.au, steve.chadban@email.cs.nsw.gov.au

Keywords: cyclosporin; diabetes; kidney transplant; outcome; tacrolimus

The first 10% of the full text of this article appears below.

The capacity to prevent acute rejection has been paramount in the minds of most clinicians in selecting an immunosuppressive strategy for kidney transplant recipients. This was certainly reasonable during the 1970s, 1980s and 1990s, as acute rejection was a common cause of graft loss. As efficacy improved over that period of time, rates of acute rejection fell and 1-year graft survival surpassed 90%. Although rates of graft loss beyond the first year remained unchanged, the reductions in early graft loss produced equal improvements in 5- and 10-year graft survival [1].

Since the 1990s, rates of acute rejection have continued to fall; however, this has not been associated with further improvements in short- or long-term graft survival [2,3]. One reason is that acute rejection is no longer a major contributor to graft loss, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?